BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
|Articles|August 1, 2001
- Pharmaceutical Technology-08-01-2001
- Volume 2001 Supplement
- Issue 2
Partnerships in Drug Discovery
Author(s)Jo Whelan
To maximize the value of outsourcing, pharmaceutical and biotech companies are realizing the importance of close partnerships with their contract service providers.
Advertisement
Articles in this issue
over 25 years ago
Creating a Successful Partnership with a Contract Manufacturerover 25 years ago
Outsourcing Outlookover 25 years ago
Creative Solutions in Client-CRO Relationshipsover 25 years ago
Third-Party Technology Transferover 25 years ago
The Squeeze in Contract Manufacturingover 25 years ago
Stakes Rise for Blown BatchesAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AAPS PharmSci 360 2026: Spray Drying and ASD
5